To the full analysis
Cigna stock: growth
CICigna reported $274.95B in revenue for fiscal 2025, up 11.3% on the prior year, up 11.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.9%
per year from 2006 to 2025, per share 17.3%
Earnings (Annual rate)
9%
per year from 2006 to 2025, per share 10.3%
Free cash flow (Annual rate)
15.9%
per year from 2006 to 2025, per share 17.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 11.4% | 21.9% | 15.9% |
| Revenue per share | 18.7% | 21.5% | 17.3% |
| Earnings | −6.8% | 11.0% | 9.0% |
| Earnings per share | −0.8% | 10.6% | 10.3% |
| Free cash flow | −1.9% | 14.3% | 15.9% |
| Free cash flow per share | 4.5% | 13.9% | 17.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $16.55B | $1.16B | $506M |
| 2007 | $17.62B | $1.12B | $1.08B |
| 2008 | $19.1B | $292M | $1.4B |
| 2009 | $18.41B | $1.3B | $438M |
| 2010 | $21.07B | $1.28B | $1.44B |
| 2011 | $21.63B | $1.26B | $1.07B |
| 2012 | $29.12B | $1.62B | $1.94B |
| 2013 | $32.38B | $1.48B | $192M |
| 2014 | $34.91B | $2.1B | $1.52B |
| 2015 | $37.88B | $2.09B | $2.21B |
| 2016 | $39.84B | $1.87B | $3.57B |
| 2017 | $41.81B | $2.24B | $3.62B |
| 2018 | $48.65B | $2.64B | $3.24B |
| 2019 | $153.57B | $5.1B | $8.44B |
| 2020 | $160.4B | $8.46B | $9.26B |
| 2021 | $174.07B | $5.37B | $6.04B |
| 2022 | $180.52B | $6.7B | $7.36B |
| 2023 | $195.27B | $5.16B | $10.24B |
| 2024 | $247.12B | $3.43B | $8.96B |
| 2025 | $274.95B | $5.96B | $8.39B |
Revenue by segment
How Cigna Corporation makes its money and how that has shifted. Names are as the company reports them.
- Evernorth85%
- Cigna Healthcare17%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Evernorth | $198.18B | $234.95B | 85.5% |
| Cigna Healthcare | $47.53B | $47.41B | 17.2% |
| Total revenue | $247.12B | $274.95B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 May 2024)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.